TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Agreement of Angle-Opening Distance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of Trabecular-Iris Space Area measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Assessment of Sensorimotor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 1 Solicited Injection Site and Systemic Reactions Post-Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of chair stands in 30 seconds (chair stand test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vitals and distance walked via 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PNH clones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sustained Moderate Visual Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from determination of need for vascular access to administration of first dose of paralytic agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time from vascular access to intubation first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time from vascular access to successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Basic Lower Limb Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of SAEs and device- &/or procedure-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with maintenance of the major Cobb angle less than or equal to 40 degrees at 60 months post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of deliveries before week 34 of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Chronic neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Propofol usage in milligrams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of change in anaesthesia depth using Bi-spectral index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in predominant enterotypes and diversity of fecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Optimal tolerated dose (OTD) of CRAd 3/5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (complete response [CR] + partial response [PR]) of CRAd 3/5-delta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Magill forceps
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete primary wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Change in WOMAC A (Pain) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Hot flash reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Serum Steroid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Balance Evaluation Systems Test (BESTest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D)
Endpoint domain: Resource use
Primary endpoint: Crowding Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with KALPA X™ device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: LAA maximum diameter and perimeter assessed by KALPATM compared to cardiac CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Multi-Modality Assessment of Immediate Post-LAAC Peri-Device Leak (PDL) by TEE and KALPA X™
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device- and/or Procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Rhinitis Symptom Severity (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rhinitis Symptoms (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of four urinary biomarkers of acrylamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of two hemoglobin adducts of acrylamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants with a 28-Joint Disease Activity Score (DAS28) < 2.6 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Clinical Global Impressions (CGI) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: influenza vaccination coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Time to Complete a 100 Meter Timed Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preparation for death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: calcium, vitamin D, zinc and ferrum serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lipase and amylase enzyme pancreatic serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: dietary intake per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: concentrations of intratumoral kinase inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Tolerated the Maximal Dose of LDE-225
Endpoint domain: Adverse events/effects
Primary endpoint: Resection Rate of Two Preoperative Chemotherapy Regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postpolypectomy bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Upper Extremity Motor Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of people asked about suicidal thoughts
Endpoint domain: Adverse events/effects
Primary endpoint: Homoarginine serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genomic location of enhancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of signatures of airway inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor response to medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Highest value of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic Insulin Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantitative Measurements of Visceral and Peripheral Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbo-pelvic motor control (LPMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance (Center of pressure area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance (Sway velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance (expert judging)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jump speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of gonalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline systolic blood pressure at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline diastolic blood pressure at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progressive Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Stage of diabetic polyneuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of diabetic polyneuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropathy symptoms and impairment scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CT scans utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Overall Macpherson Modification of the Lobene Stain Index (MLSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sales of kids' menu items
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean AM Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma glucagon-like peptide-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adequacy of nasotracheal tube tip location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative decrease in protection against pertussis disease (PCR-confirmed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Subjects Able to Complete the 600 Meter Walk Test (600MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Speed of 10 Meter Walk Test (10MWT) Mid Study Versus End of Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go (TUG) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat Treatment Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of delayed growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of delayed puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of lipodystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of blood lipids and glucose abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of delayed growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of delayed puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulatory blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in endothelial function measured by reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recruitment/Retention Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dental biofilm pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of IFNLR1/IL28Ra in human neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent time laughing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent time expressing empathy for others
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of time spent in substantive conversations
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percent of time spent alone
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pulmonary function measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Laryngeal protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum Alanine Transaminase (ALT) levels response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: liver fat response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: abnormal bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median time to pseudocyst recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident Cases in 6 months
Endpoint domain: Mortality/survival
Primary endpoint: S. pneumoniae antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Colonic Transit Time (CTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Systemic response to the implanted scaffold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local response to the implanted scaffold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of second stage labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiac and Neurological Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in substance abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of HEWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Scores of Comfort on Insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of re-operation due to Cerebrospinal Fluid leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Scale for Maternal Satisfaction in Vaginal Delivery (SMSVD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage reduction of treated areas from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Activities-specific Balance Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Falls Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tolerability of drug
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiologic clearance of Cryptococcus from the CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dehiscence and fistula formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Annual Asthma Exacerbation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Pain Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change Tongue Maximal Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of addiction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Have a ≥4-point Improvement in the Weekly Mean Score of ASDD Item #2 From Baseline at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of therapy (DOT)/admission
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Fibromyalgia Impact Questionnaire (FIQ) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Daily Pain and/or Bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-traumatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of the insulin/glucose ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of abdominal pain VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UPDRS Parts II and III total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Any Infusion Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in daily bout-related and total moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily percentage of waking hours spent in sedentary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Daytime Nasal Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in DTI parameters (FA and MD) in sural nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline - Intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change from baseline - Conjunctival hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: New fragility vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Device Malfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Combined Pain Severity and Interference Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pedometer measured steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methionine Elimination Half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in lumbar spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SN detection rate during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: p24 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in erosive esophagitis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in esophageal acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in clinical symptoms of reflux disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to First Atrial Fibrillation (AF) Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of grafts patent at 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma Concentration of OPC-14597
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in CMAP M-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Poor outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Beck Depression Inventory II (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Depression Inventory II (BDI II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression Anxiety Stress Scales (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aulhorn Stage (Visual Field Defects)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Optic Disc Excavation: Vertical Cup to Disc Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Optic Disc Excavation: Horizontal Cup to Disc Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of p53/L1CAM/ER/PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Presence or absence of ear wax cap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of combined vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change of 2-h Post Prandial Blood Glucose (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Validation of diagnostic algorithm for hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes